Graforce presents plasma electrolysers for hydrogen from methane and wastewater on IFAT 2022 fair
25.5.2022 11:00:00 EEST | Business Wire | Press release
Green hydrogen is key to achieving a circular economy. Graforce has developed a plasma electrolysis technology that can produce hydrogen from residual materials – with significantly lower manufacturing costs and higher yields. Graforce will be demonstrating its marketable methane and wastewater electrolysis plants and refueling systems at IFAT, the world’s leading trade fair for water, sewage and waste management. They demonstrate the immense market potential of green hydrogen and the range of applications for CO2-free or even CO2-negative energy and fuel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005029/en/
Graforce plasma electrolysis plants (here a plant in Berlin) produce green hydrogen from methane, wastewater, liquid manure or ammonia. Whereas water electrolysis needs 50kWh/kg H2, the production of 1kg hydrogen from methane takes only 10kWh or 20kWh from wastewater. (Photo: Graforce)
Green hydrogen is projected to have a game changing impact in the mobility, industry, and decentralized energy segments. It plays an important role in meeting global climate goals. The global hydrogen market is forecast to grow by a factor of 6 by 2050. Germany makes up 20 percent of the current European hydrogen consumption and is also forecast to remain the largest hydrogen off-take market in the EU, driven by strong decarbonization commitments across sectors.
The production of hydrogen using plasma electrolysis requires considerably less energy than water electrolysis and leads to significant cost reductions. Whereas water electrolysis needs 50kWh/kg H2, the production of 1kg hydrogen from methane takes only 10kWh or 20kWh from wastewater.
“Whether as fuel, heat source or a raw material, green hydrogen can make a significant contribution to achieving climate targets in many industries,” explains Dr. Jens Hanke. “Our plants produce green hydrogen from methane, wastewater, liquid manure or ammonia. We thus close energy and material cycles and make a significant contribution to a future without fossil fuels and CO2 emissions. And we deliver this quickly and cost-effectively."
For the development and customer-specific scaling of its modular plants, Graforce works with global leaders in the fields of engineering, procurement, and construction. The company is currently in the process of expanding its strategic partnerships with financial as well as strategic investors to quickly scale its technology worldwide.
About
The German company Graforce is a technology leader in sustainable solutions and carbon dioxide removal technologies. The power-to-X plants produce CO2-free or CO2-negative hydrogen and synthetic feedstocks – with the highest efficiency and lower infrastructure costs in the multi-megawatt range. Thus, Graforce decarbonizes fossil energies, industrial sectors and the heat, transport and building sectors. www.graforce.com/EN
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005029/en/
Contact information
Graforce GmbH
Dr. Jens Hanke
Phone: +49 30 - 63 2222-110
presse@graforce.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release
Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom